Eptifibatide

Excerpt

Eptifibatide is a glycoprotein IIb/IIIa class platelet inhibitor drug that reduces ischemic cardiac events in specific patient populations. The FDA has approved this medication for the medical management of unstable angina and non-ST elevation myocardial infarction (NSTEMI). The FDA also approved eptifibatide for patients undergoing percutaneous intervention (PCI), including intracoronary stenting. The IMPACT-II trial proved that eptifibatide use with heparin and aspirin reduces ischemic events following a PCI, especially in individuals with unstable angina.